Organon & Co. (OGN)
| Market Cap | 8.76B |
| Revenue (ttm) | 6.37B |
| Net Income (ttm) | 1.30B |
| Shares Out | 253.64M |
| EPS (ttm) | 5.14 |
| PE Ratio | 6.72 |
| Forward PE | 5.03 |
| Dividend | $1.12 (3.24%) |
| Ex-Dividend Date | May 13, 2022 |
| Volume | 248,737 |
| Open | 35.05 |
| Previous Close | 34.79 |
| Day's Range | 34.45 - 35.09 |
| 52-Week Range | 28.42 - 39.48 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 40.22 (+16.4%) |
| Earnings Date | Aug 11, 2022 |
About OGN
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of seve... [Read more...]
Financial Performance
In 2021, Organon & Co.'s revenue was $6.30 billion, a decrease of -3.49% compared to the previous year's $6.53 billion. Earnings were $1.35 billion, a decrease of -37.45%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for OGN stock is "Buy." The 12-month stock price forecast is 40.22, which is an increase of 16.41% from the latest price.
News
In a Sour Market, These Stocks Have Been Sweet
While most stocks have nosedived this year, a few have gained altitude.
Organon Enters into Global License Agreement to Commercialize Henlius' Investigational Perjeta® (Pertuzumab) and Prol...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces first biosimilars business deal with a global license agreement with Henlius.
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #ESG--On one year anniversary, Organon introduces global ESG strategy & goals with the launch of Her Promise platform & publication of inaugural ESG report
Organon (OGN) Q1 Earnings and Revenues Beat Estimates
Organon (OGN) delivered earnings and revenue surprises of 25.95% and 3.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up
Organon easily beat first-quarter expectations Thursday despite a dive for its flagship product, Nexplanon, and OGN stock popped. The post Organon Easily Beats First-Quarter Expectations Despite Nexplan...
Organon Reports Results for the First Quarter Ended March 31, 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (the “company”), today announced its results for the first quarter ended March 31, 2022. "The first quarter marked a solid start to the year. We c...
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Organon (OGN) is Poised to Beat Earnings Estimates Again
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for treating bacterial...
3 of the Best Value Stocks to Buy Heading Into April
With these shares at modest valuations, you can score some cheap long-term investments.
Organon To Present at the Cowen 42nd Annual Healthcare Virtual Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...
Meghan Rivera Appointed US Managing Director, Organon
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Meghan Rivera Appointed US Managing Director, Organon
Organon Shares Up About 7% Since Merck Spinoff
Shares of Organon & Co. ( OGN , Financial) are up nearly 7% since the pharma company was spun off by Merck & Co. Inc. ( MRK , Financial) in the middle of 2021. And even bluer skies appear to be on the h...
Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B
Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily by Nexplanon, which increased 37% ex-FX.
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon reports results for the fourth quarter and full year ended December 31, 2021
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People's Republic of China, including Hong K...
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Acquires Marvelon® and Mercilon®, in the People's Republic of China, including Hong Kong, Macau, Agrees to Acquire these Products in Vietnam
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon to report 4th Quarter and full year 2021 earnings
Why Organon (OGN) Could Beat Earnings Estimates Again
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
FDA Accepts Samsung Bioepis' and Organon's sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosi...
INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--FDA Accepts Samsung Bioepis' and Organon's sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon CEO and CFO to participate in JP Morgan Conference Fireside Chat
Organon's acquisition of Karolinska Development's portfolio company Forendo Pharma has been successfully completed
STOCKHOLM SWEDEN – December 13, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the previously announced transaction, in which the global pharmaceutical company Organon & C...
Organon Completes Acquisition of Forendo Pharma
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Endometriosis--Organon Announces Close of Forendo Pharma
Karolinska Development AB (publ) proposes a rights issue of approximately SEK 491 million, and publishes a proposal f...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, HONG KONG, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES O...